ACCELERATED MASS PRODUCTION OF INFLUENZA VIRUS SEED STOCKS IN HEK-293 SUSPENSION CELL CULTURES BY REVERSE GENETICS

Ernest Milián, Department of Bioengineering, McGill University, Montréal, Québec, Canada  
ernest_milian@me.com  
Thomas Julien, Virologie et Pathologie Humaine (VirPath Team) -VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Université de Lyon, France  
Rafael Biaggio, Department of Bioengineering, McGill University, Montréal, Québec, Canada.  
Alina Venereo-Sanchez, Department of Bioengineering, McGill University, Montréal, Québec, Canada  
Johnny Montes, Vaccine Program, Human Health Therapeutics, National Research Council, Canada  
Danielle Jacob, Vaccine Program, Human Health Therapeutics, National Research Council, Canada  
Aziza P. Manceur, Vaccine Program, Human Health Therapeutics, National Research Council, Canada  
Sven Anzorge, Vaccine Program, Human Health Therapeutics, National Research Council, Canada  
Emma Petiot, CPE Lyon, Campus LyonTech-la Doua, Lyon, France  
Manuel Rosa-Calatrava, Virologie et Pathologie Humaine (VirPath Team) -VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Université de Lyon, France  
Amine Kamen, Department of Bioengineering, McGill University, Montréal, Québec, Canada, Vaccine Program, Human Health Therapeutics, National Research Council, Montréal, Québec, Canada

Key Words: Influenza virus, Vaccines, Candidate Vaccine Virus (CVV), Suspension cell culture, Reverse Genetics.

Despite major advances in developing capacities and alternative technologies to egg-based production of influenza vaccines, responsiveness to an influenza pandemic threat is limited by the time it takes to generate a Candidate Viral Vaccine (CVV) as reported by the 2015 WHO Informal Consultation report titled “Influenza Vaccine Response during the Start of a Pandemic”. In previous work, we have shown that HEK-293 cell culture in suspension and serum free medium is an efficient production platform for cell culture manufacturing of influenza candidate vaccines. This report, took advantage of, recombinant DNA technology using Reverse Genetics of influenza A/Puerto Rico/8/34 H1N1 strain, and advances in the large-scale transfection of suspension cultured HEK-293 cells. Transfection in shake flasks was performed using 1µg of total plasmid and 1x10^6 cells/mL. The supernatant was harvested after 48 hpt and used to infect a new shake flasks at 1x10^6 cells/mL for virus amplification. 3-L bioreactor was inoculated and transfected at 1x10^6 cells/mL with 1µg of total plasmid and harvested after 48hpt and the virus generated was amplified in shake flask. Quantification by TCID50, SRID, Dot-blot and TRPS were performed as well as characterization by TEM and HA and NA sequencing. Small-scale transfection in shake flasks generated 1.5x10^6 IVP/mL after 48 hpt and 1x10^7 IVP/mL after 96 hpi. For large-scale experiment a 3-L controlled stirred tank bioreactor resulted in supernatant (P0) virus titer of 5x10^4 IVP/mL and 2.8x10^7 IVP/mL after only one amplification (P1) in HEK-293 suspension cells. We demonstrate the efficient generation of H1N1 with the PR8 backbone reassortant under controlled bioreactor conditions in two sequential steps (transfection/rescue and infection/production). This approach could deliver a CVV for influenza vaccine manufacturing within two-weeks, starting from HA and NA pandemic sequences. Thus, this innovative approach is better suited to rationally design and mass produce the CVV within timelines dictated by pandemic situations and produce effective responsiveness than previous methodology.